GW Pharmaceuticals PLC- (NASDAQ:GWPH) Downgraded by BidaskClub to “Sell”

BidaskClub lowered shares of GW Pharmaceuticals PLC- (NASDAQ:GWPH) from a hold rating to a sell rating in a report published on Saturday morning, BidAskClub reports.

Several other equities research analysts also recently commented on GWPH. Needham & Company LLC assumed coverage on shares of GW Pharmaceuticals PLC- in a research note on Monday, October 21st. They issued a buy rating and a $200.00 target price for the company. Zacks Investment Research raised shares of GW Pharmaceuticals PLC- from a hold rating to a buy rating and set a $122.00 target price for the company in a research note on Saturday. Cantor Fitzgerald reaffirmed an overweight rating and issued a $174.00 target price on shares of GW Pharmaceuticals PLC- in a research note on Wednesday. Bank of America reaffirmed a buy rating and issued a $218.00 target price on shares of GW Pharmaceuticals PLC- in a research note on Wednesday, September 25th. Finally, Oppenheimer lowered their target price on shares of GW Pharmaceuticals PLC- to $222.00 and set an outperform rating for the company in a research note on Wednesday. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and fourteen have issued a buy rating to the stock. GW Pharmaceuticals PLC- has an average rating of Buy and an average price target of $198.00.

NASDAQ:GWPH traded up $0.37 on Friday, reaching $109.41. The stock had a trading volume of 1,981,100 shares, compared to its average volume of 510,536. GW Pharmaceuticals PLC- has a 1-year low of $90.14 and a 1-year high of $196.00. The company has a quick ratio of 7.59, a current ratio of 8.31 and a debt-to-equity ratio of 0.03. The company has a market capitalization of $4.16 billion, a P/E ratio of -10.36 and a beta of 2.28. The stock has a fifty day moving average price of $122.70 and a 200-day moving average price of $154.23.

In other news, insider Douglas B. Snyder sold 5,424 shares of the stock in a transaction on Monday, August 19th. The shares were sold at an average price of $13.04, for a total transaction of $70,728.96. Following the completion of the sale, the insider now owns 73,740 shares of the company’s stock, valued at $961,569.60. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Douglas B. Snyder sold 3,756 shares of the stock in a transaction on Monday, August 12th. The stock was sold at an average price of $13.88, for a total transaction of $52,133.28. Following the sale, the insider now directly owns 79,164 shares of the company’s stock, valued at approximately $1,098,796.32. The disclosure for this sale can be found here. 3.60% of the stock is owned by corporate insiders.

Several hedge funds have recently modified their holdings of GWPH. Point72 Asset Management L.P. increased its position in shares of GW Pharmaceuticals PLC- by 1,837.0% during the second quarter. Point72 Asset Management L.P. now owns 670,511 shares of the biopharmaceutical company’s stock worth $115,589,000 after acquiring an additional 635,895 shares in the last quarter. ETF Managers Group LLC bought a new stake in shares of GW Pharmaceuticals PLC- during the second quarter worth $99,346,000. Victory Capital Management Inc. increased its position in shares of GW Pharmaceuticals PLC- by 82.7% during the second quarter. Victory Capital Management Inc. now owns 747,015 shares of the biopharmaceutical company’s stock worth $128,778,000 after acquiring an additional 338,075 shares in the last quarter. Nuveen Asset Management LLC bought a new stake in shares of GW Pharmaceuticals PLC- during the second quarter worth $32,687,000. Finally, Marshall Wace North America L.P. increased its position in shares of GW Pharmaceuticals PLC- by 47.1% during the second quarter. Marshall Wace North America L.P. now owns 466,062 shares of the biopharmaceutical company’s stock worth $80,345,000 after acquiring an additional 149,163 shares in the last quarter. 82.89% of the stock is owned by institutional investors.

GW Pharmaceuticals PLC- Company Profile

GW Pharmaceuticals plc, a biopharmaceutical company, focuses on discovering, developing, and commercializing cannabinoid prescription medicines using botanical extracts derived from the Cannabis plant. Its lead product is Epidiolex, an oral medicine for the treatment of refractory childhood epilepsies, as well as for the treatment of Dravet syndrome, Lennox-Gastaut syndrome, tuberous sclerosis complex, and infantile spasms.

Further Reading: What does the Dow Jones Industrial Average (DJIA) measure?

Analyst Recommendations for GW Pharmaceuticals PLC- (NASDAQ:GWPH)

Receive News & Ratings for GW Pharmaceuticals PLC- Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GW Pharmaceuticals PLC- and related companies with MarketBeat.com's FREE daily email newsletter.